| 2
This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified
by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” and similar terms and phrases.
Forward-looking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current
expectations, including statements relating to the timing of the initiation of the clinical trials, including the expansion phase of the Phase 1/2a trial to evaluate LAVA 1207 in
combination with KEYTRUDA®, the timing of regulatory submissions, including an IND of LAVA-1266 in AML and LAVA's cash runway and the sufficiency of resources to
pursue development. Forward-looking statements are based on our management’s beliefs and assumptions and information currently available to our management. Such
statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various
important factors. These risks and uncertainties include, among other things; the timing and results of our research and development programs, preclinical studies and
clinical trials, including the availability of data therefrom, expectations regarding enrollment in clinical trials, the timing of our clinical trial for LAVA-1207, and the submission
of INDs or CTAs for our other product candidates; the expected safety profile of LAVA’s product candidates; our ability to develop and obtain regulatory approval for and
commercialize any of our product candidates; potential uses of LAVA’s product candidates to treat various tumor targets, including AML, MDS, mCRPC, CRC, NSCLC, and
HNSCC, and improve patient outcomes, the ability of low-dose interleukin-2 to increase the number of V9V2 T cells available for engagement by LAVA’s product candidates;
the relationship between V2 T cells and antitumor activity; the potential synergies between LAVA’s product candidates and other immuno-oncology approaches; the
potential market opportunity our product candidates seek to address; our intellectual property position; the ability of LAVA’s collaborators to support or advance
collaborations or our product candidates; any payments to us under our license agreement with LAVA’s collaborators or our agreements with our collaborators and our cash
runway; our ability to leverage our initial programs to develop additional product candidates using our Gammabody® platform; and the risk that positive results in a
preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials. In
addition, there may be adverse effects on our business condition and results of operations from general economic and market conditions and overall fluctuations in the
United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation, interest rates, the Russian invasion of
Ukraine and the Israel-Hamas war. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from
those contained in the forward‐looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the
filings we make with the Securities and Exchange Commission from time to time.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our
control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, the events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results
could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.
Any forward-looking statements represent the Company’s views only as of the date of this presentation and do not represent its views as of any subsequent date. The
Company explicitly disclaims any obligation to update any forward-looking statements.
Legal Disclosure: Forward-looking Statements |